Direct-to-consumer drug advertising has changed dramatically over the past decade. What began as cautious messaging about serious medications has evolved into lifestyle marketing: smiling actors, golden retrievers, and promises of freedom, energy, and “getting back to what matters.”
The problem is simple. Many of these drugs are not lifestyle enhancers. They are immune-altering, metabolic-altering, or infection-risk-altering agents. And the public is not hearing the truth.
As a developmental-behavioral pediatrician, I spent decades watching how vulnerable populations respond to infection, inflammation, and chronic disease. Now, as a patient, I see the other side of the equation: powerful medications marketed as if they were cosmetic upgrades. The gap between the ads and the physiology is widening.
Immunosuppressants: cheerful ads, serious risks
Biologics and small-molecule immunosuppressants for psoriasis, rheumatoid arthritis, Crohn’s disease, and other autoimmune conditions suppress cytokine pathways that are essential for host defense. TNF-alpha blockers, IL-17 inhibitors, IL-23 inhibitors, and JAK inhibitors all carry risks that include:
- Opportunistic infections
- TB reactivation
- Fungal disease
- Malignancy
- Sepsis
- Death
Yet in the ads, these risks appear in a rapid-fire whisper at the end, sandwiched between “ask your doctor” and “you may qualify for savings.” The tone is almost surreal. Death is listed in the middle of the side effects, but the actors are dancing in a meadow.
Real physician voices, twice a week
Free, and one click to unsubscribe.
Immunosuppression is not a lifestyle choice. It is a medical state.
The forgotten diseases: TB, measles, pertussis
TB is almost forgotten in the United States, but reactivation is a known risk with TNF-alpha suppression. Measles and pertussis have resurged in pockets of undervaccinated communities. RSV remains a constant pediatric threat. Millions of adults are now immunosuppressed, interacting daily with children who carry respiratory viruses with ease.
The public has no idea what immunosuppression actually means. The ads certainly don’t explain it.
GLP-1s and SGLT2 inhibitors: powerful drugs, lifestyle marketing
Glucagon-like peptide-1 (GLP-1) receptor agonists (Ozempic, Wegovy, Trulicity) are potent metabolic drugs. They slow gastric emptying, alter appetite, and change insulin dynamics. They are not benign. They carry risks of pancreatitis, gallbladder disease, and gastrointestinal complications. Yet they are marketed as weight-loss miracles.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors (Farxiga, Jardiance) are equally powerful. They force glucose excretion through the kidneys, reduce intraglomerular pressure, and improve cardiac outcomes. They also carry risks of dehydration, ketoacidosis, urinary infections, and rare but real warnings such as lower-extremity amputation.
I take Farxiga myself. It improved my eGFR to above 60 and helped normalize my ejection fraction. It works. But it is not a lifestyle drug. It is a serious medication with serious physiology behind it.
The problem is not the drugs. The problem is the marketing.
The new loophole: celebrity telehealth without disclaimers
A world-famous athlete now promotes a direct-to-consumer telehealth platform. The ads are polished, empowering, and upbeat. They promise convenience, control, and “the care you deserve.” What they do not include is the mandatory FDA risk disclosure required for prescription drug advertising.
Because the platform is not advertising a specific drug. It is advertising access to drugs. That is the loophole.
A celebrity can promote a pipeline to prescription medications without listing:
- Infection risks
- Metabolic risks
- Psychiatric risks
- Contraindications
- Monitoring requirements
- Drug interactions
The viewer hears none of it. Business models like this can depend on rapid prescribing. The disclaimers are minimal. The risks are invisible. This is dangerous.
The pediatrician’s warning: a growing vulnerable population
We are creating a large population of adults whose immune systems or metabolic systems are altered by chronic medication. They interact with children every day: children who carry RSV, influenza, pertussis, and measles with ease. The public health implications are not theoretical. We are conditioning millions of Americans to take powerful immune-altering or metabolic-altering drugs without understanding the consequences.
The call for honesty
This is not an argument against immunosuppressants, GLP-1s, or SGLT2 inhibitors. Many of these medications are transformative. Some save lives. Some improve cardiac function, renal function, or quality of life. The issue is not the drugs. The issue is the messaging.
Patients deserve honest risk communication. They deserve clarity, not lifestyle marketing. They deserve disclosure, not celebrity-endorsed pipelines.
Immunosuppression is not a cosmetic upgrade. Metabolic alteration is not a wellness trend. Prescription access is not empowerment without information.
It is time to stop whispering the risks.
Ronald L. Lindsay is a retired developmental-behavioral pediatrician whose career spanned military medicine, academic leadership, and national advocacy for dignity-centered neurodevelopmental care. His NIH-funded work with the RUPP Autism Network helped define evidence-based approaches to autism and related developmental disorders.
He directed the LEND Program at The Ohio State University and founded JBLM CARES, a $10 million autism resource center for military families. His writing spans clinical scholarship and long-form fiction. He is the author of The Mercy Directive and the six-novel Cassandra series, a completed political and medical fiction saga tracing the rise of the Cassandra system from its origins to its national and international legacy. His forthcoming memoir, The Quiet Architect, examines how conscience and structure collide in modern medicine.
He shares updates on LinkedIn.
